Intermittent Claudication Clinical Trial
Official title:
The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication
Intermittent claudication (IC) is caused by peripheral arterial disease and has a high
morbidity and mortality. Etiologic factors are similar to those of cardiovascular disease.
Primary treatment consists of cardiovascular risk management and improvement of functional
capacity with supervised exercise therapy (SET). A potential additional therapy is the
administration of fish oil supplements containing high amounts of omega-3 Poly Unsaturated
Fatty Acids (PUFAs). In earlier clinical and experimental trials omega-3 PUFA's improved
hemorheological parameters such as erythrocyte deformability and aggregation, and a number of
cardiovascular risk factors. Hemorheological parameters determine the blood flow in the
microcirculation, which is of main importance in patients with IC since the macrocirculation
is compromised. Inflammation is considered an important etiologic factor in the pathogenesis
of atherosclerosis and contributes to peripheral arterial disease Since omega-3 PUFAs also
have a strong anti-inflammatory effect, they might be effective in patients with IC by
lowering the inflammatory response. In addition, visceral fat rather than obesity in general
has been recognised as an etiologic and prognostic factor in atherosclerosis.
We hypothesise that the administration of omega-3 PUFA's in patients with IC has a
synergistic effect with SET and improves walking distance after SET, by improving
hemorheological parameters resulting in a better microcirculation. Second, we hypothesise
that omega-3 PUFA's result in a less proinflammatory of whole blood in response to ex vivo
stimulation with endotoxin. Third, we hypothesise that omega-3 PUFA's and SET result in a
decrease in visceral fat mass.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400395 -
Clinical Trial for GNX80 in Intermittent Claudication
|
Phase 4 | |
| Active, not recruiting |
NCT02341716 -
Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication
|
N/A | |
| Completed |
NCT02041169 -
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia
|
N/A | |
| Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
| Recruiting |
NCT00538408 -
Whole Body Magnetic Resonance Angiography in Ischemic Patients
|
N/A | |
| Completed |
NCT00388128 -
Caffeine and Intermittent Claudication
|
Phase 3 | |
| Completed |
NCT00618670 -
Home-based vs. Supervised Exercise for People With Claudication
|
N/A | |
| Recruiting |
NCT00146666 -
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
|
Phase 2 | |
| Completed |
NCT00134277 -
Trial Comparing Different Medical Devices for Infragenual Dilatation
|
N/A | |
| Completed |
NCT01256775 -
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
|
Phase 2 | |
| Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06299956 -
Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark
|
N/A | |
| Not yet recruiting |
NCT05335161 -
A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
|
Phase 1 | |
| Completed |
NCT04390282 -
Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication
|
N/A | |
| Completed |
NCT03271710 -
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
|
N/A | |
| Completed |
NCT02380794 -
Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule
|
Phase 2 | |
| Active, not recruiting |
NCT02276937 -
Randomized Phase IIb Trial of DVC1-0101
|
Phase 2 | |
| Completed |
NCT02097082 -
Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
|
N/A | |
| Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
| Completed |
NCT00071266 -
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
|
Phase 3 |